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Summary Early liver metastases have a predominant portal blood supply. Intraportal (i.port.) vein admini-
stration of cytotoxics could theoretically achieve enhanced drug concentrations in tumour cells and be effective
as adjuvant therapy after resection of colorectal carcinoma. Pirarubicin (which has a higher hepatic extraction
than doxorubicin) was investigated on liver metastases of the VX2 rabbit tumour, which were of less than
2 mm in diameter 7 days after cells injection into the portal vein. To evaluate antitumour activity, 24 rabbits
were randomised into three groups 7 days after implantation: (a) control, (b) i.v. pirarubicin, (c) i.port.
pirarubicin at doses of 2 mg kg-' in both groups. Portal infusions led to no hematological or hepatic toxicity.
Pharmacokinetic parameters showed a significantly reduced systemic exposure after i.port. administration.
Fourteen days after treatment, livers and lungs were analysed. The mean number (± s.d.) of tumour foci was
(a) 8.62 (± 5.4), (b) 4.62 (± 3.2), (c) 2.25 (± 1.4) (P<0.05 a vs c). The mean tumour area was (a) 6.31 (± 6.1),
(b) 1.31 (± 2.2), (c) 0.43 (± 0.4cm2) (P<0.05 a vs c) and the percentage (95% C.I.) of rabbits with lung
metastasis was: (a) 87.5% (47-99%), (b) 75% (35-97%), (c) 12.5% (3-52%) (P<0.02 b vs c). Intraportal
pirarubicin seems to be well tolerated and more efficient than i.v. administration, particularly in preventing
extrahepatic dissemination.
Residual cancer cells are responsible for treatment failures
after curative resection for colorectal cancer and the liver is
the most frequent site of relapse (Willett et al., 1984).
Systemic post-operative adjuvant therapy based on
fluoropyrimidines can reduce the recurrence rates and in-
crease overall survival, as recently observed in Dukes C stage
colon cancer (Moertel et al., 1992). With new active drugs
and a more efficient targeting of tumour tissues, further
improvements could be obtained.
Colon cancer cells disseminate through the mesenteric
veins and portal system (Fisher & Turnbull, 1955), and the
newly growing liver metastases receive their blood supply
from the portal branches, until they develop a main arterial
vascularisation (Conway et al., 1983; Ackerman, 1986). Fac-
tors such as intraoperative manipulation of the tumour,
perioperative impaired immunity and stress, have been
reported to facilitate the dissemination and seeding of malig-
nant cells. Regional post-operative adjuvant therapy via the
portal vein could be an effective means of preventing the
development of liver metastases, by delivering higher local
drug concentrations to tumour cells at the onset of metastatic
invasion. Several clinical trials have been designed to test this
hypothesis (Taylor et al., 1985; Gray et al., 1987; Ryan et al.,
1988; Wolmark et al., 1990; Metzger et al., 1990; Wereldsma
et al., 1990; Beart et al., 1990; Fielding et al., 1992). Most of
them used 5-FU alone, or in association with mitomycin C in
different schedules. Current results are controversial and
remain inconclusive. Some trials have shown a reduction in
the number of hepatic recurrences with no benefit for overall
survival (Wereldsma et al., 1990). Others have demonstrated
an increase in overall and disease free survival, although no
differences were noted in the number of hepatic recurrences
(Wolmark et al., 1990).
Other antitumoural compounds could be tested for
regional therapy, focusing on drugs with a high hepatic
extraction and limited heptatic toxicity. Anthracyclines, are
generally considered inactive against colorectal cancer, but
pirarubicin, a new derivative, has been recently investigated
in pre-clinical and clinical studies (Miller & Schmidt, 1987).
This compound has a faster cellular uptake than that of
doxorubicin (Munck et al., 1985), as it is much more
lipophilic. Indeed, the apparent partition coefficient (Papp)
between octanol and phosphate buffer at pH 7 is 35.8 (log
P: 1.55) for pirarubicin, and 0.26 (log P: - 0.59) for doxo-
rubicin (unpublished data). Furthermore, pirarubicin has
demonstrated its superiority over doxorubicin in an experi-
mental study with intraarterial hepatic (i.a.h.) administration
which appeared essentially due to a greater tumour drug
uptake (Munck et al., 1993). Subsequent clinical studies have
further demonstrated a high degree of activity, even against
colorectal hepatic metastases (Munck et al., 1990). This
prompted our investigation of the putative benefit of in-
traportal infusion of adjuvant pirarubicin in the experimental
VX2 tumour in the rabbit.
The present study, on a model of early experimental liver
metastases, compares intraportal (i.port.) vs intravenous (i.v.)
adjuvant infusion of pirarubicin, taking into account both
pharmacokinetic parameters and the effects of this cytotoxic
on hepatic and extrahepatic tumoural growth and dissemina-
tion.
Materials and methods
Animals and anaesthesia
Female New Zealand white rabbits weighing 2.7-3.2 kg were
used (Elevage Scientifique des Dombes, Romans, France).
The rabbits were maintained under standard conditions on a
laboratory diet and water ad libitum. All procedures were
carried out under general i.v. anaesthesia using ketamine
hydrochloride (50 mg kg-'; KetamineO, Parke Davis) and
xilazine 2% (0.1 ml kg-'; Rompun®, Bayer). All experiments
were conducted in accordance with the European Council
directive 86/609/CEE, and French legislation concerning
animal welfare.
Drugs and chemicals
Doxorubicin hydrochloride, daunorubicin, doxorubicinol,
doxorubicinone, pirarubicinol, and pirarubicin hydrochloride
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were provided by Laboratoire Roger Bellon (Neuilly-sur-
Seine, France). The chemical structure of doxorubicin and
pirarubicin is depicted in Figure 1. Solvents used for extrac-
tion and high performance liquid chromatography (HPLC)
analyses were all of HPLC grade or of highest available
purity.
VX2 tumour inoculation andsurgicalprocedures
The VX2 tumor was kindly provided by Dr G. Orth (U190
INSERM, Institut Pasteur, Paris, France) and was main-
tained by serial passages in carrier rabbits. A VX2 tumour
was removed from one animal, minced in NCTC 109
medium (Eurobio, Paris, France) and filtered through a cot-
ton gauze. The filtrate was adjusted to 3 x I07 cells ml-' with
the above medium containing 10% dimethylsulfoxide
(DMSO) and 20% foetal calf serum (Gibco, Paris, France) to
constitute a homogeneous stock that was frozen in liquid
nitrogen in 1 ml aliquots and used throughout the study.
This procedure minimised inter-subject variations in tumour
growth rate.
Hepatic implantation of the VX2 carcinoma was accomp-
lished through a small median subxyphoid incision. A 1 ml
frozen sample of VX2 cells was rapidly thawed and centri-
fuged. The cell pellet was adjusted to 0.5 ml (NCTC 109
medium), and injected with a 24-gauge catheter into the main
portal vein.
Establishment ofa model ofearly hepatic metastases
In order to establish the optimal time for i.port. drug
administration, the kinetics of VX2 tumour growth after
i.port. inoculation were determined. For this purpose three
groups of four rabbits each were studied, and the animals
were sacrificed at 7, 14, and 21 days after VX2 cell injections.
Livers were cut into 5 mm slices, and the number of tumours
and their diameters were recorded and cross-sectional areas
calculated. Lung slides were screened for the presence or
absence of metastases.
Drug administration and collection ofbiological samples
Intraportal perfusions of pirarubicin were done with a 24-
gauge catheter which was inserted into the portal vein. The
drug was infused over 5 min with a pump (MS 16 A
Graseby, Michel Freres, Montreuil, France). Intravenous
perfusions were done through the auricular vein with the
same pump, and a sham laparotomy was performed so that
operative stress was similar to that of the portal perfused
group.
Doses of 2 mg kg-' of pirarubicin were administered for
pharmacokinetic studies. Heparinised blood samples (2 ml)
were drawn from the left ear artery prior to injection, and at
0.5, 2, 5, 15, 30 and 60 min thereafter. Samples were centri-
fuged (2000g, 10 min) and the plasma samples were frozen at
- 20C until HPLC analysis.
To assess local liver toxicity, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase, and total bilirubin levels were determined before
pirarubicin perfusions and 2 and 7 days thereafter.
Hematological toxicity was evaluated according to blood cell
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counts at 5, 7 and 14 days, which were compared to pre-
treatment baseline values.
Determination ofmaximal toleratedsingle i.port. doses of
pirarubicin
The maximal tolerated dose (MTD) in rabbits for the i.v.
route had been previously determined at 2 mg kg-' (unpub-
lished data). Higher i.v. doses (2.5 mgkg-') were associated
with lethal toxicity. The determination of the MTD for the
i.port. route was achieved by escalating the 2 mg kg-' dose
by 0.5 mg increments. Pirarubicin was administered at single
doses of 2 mg, 2.5 mg, 3 mg, and 3.5 mg to four groups of
four rabbits without a tumour graft.
Determination ofpirarubicin plasma concentration
Plasma concentrations were determined using reversed-phase
HPLC. Daunorubicin was added as the internal standard
(100 ngml-'). Half a ml of plasma was extracted on 100 mg
octadecyl (C18) columns (1 ml Bakerbond spe®, Baker, Phil-
lipsburg, NJ) preconditioned with 1 ml of methanol, followed
by 1 ml of water. After air drying, elution was accomplished
with 1 ml of methanol/dichloromethane (1:1, v:v) following
the addition of 200flI of DMSO. The volume was then
reduced to approximately 200ftl under a nitrogen stream
before HPLC injection. This procedure allowed a 95%
recovery of pirarubicin, internal standard and metabolites.
The HPLC system consisted of a C18 column (Nucleosil C,
10 ltm, 3.9 x 300 mm, SFCC, Neuilly-sur-Seine, France), a
Wisp automatic injector (710B, Waters Associated, Milford,
Ma, USA), a 6000A pump (Waters), and a fluorescence
detector (Shoeffel FS 970) set at 251 nm (ex.) and 550 nm
(em.). The mobile phase consisted of water (adjusted to
pH 2.4 with phosphoric acid) and acetonitrile (68:32, v:v) at
a flow rate of 1.75 mlmin-'. Under these conditions, the
retention times of doxorubicinol, doxorubicin, pirarubicinol,
daunorubicin, and pirarubicin were 3.59, 4.48, 5.94, 6.90 and
9.65 min, respectively. Two peaks corresponding to dox-
orubicinol and doxorubicin were observed in plasma after
doxorubicin injection, whereas four peaks were detected fol-
lowing pirarubicin infusion. These peaks coeluted with dox-
orubicinol, doxorubicin, pirarubicinol and pirarubicin.
Pharmacokinetic analysis
Plasma concentrations were best fitted to a two-compartment
model with first-order elimination using a 5 min i.v. infusion
input. Curve fitting was accomplished with the PC-NONLIN
nonlinear regression program (Statistical Consultants Inc.,
Lexington, KY) using a data weight of the reciprocal of the
concentration. The total area under the curve (AUC) was
determined using the trapezoidal method. The other phar-
macokinetic parameters were calculated according to stan-
dard methods (Gibaldi & Perrier, 1982).
Antitumour effects ofintravenous and intraportalpirarubicin
Eight consecutive experiments were conducted on groups of
three rabbits each in a block-design experiment. They were
inoculated and randomised to receive: no treatment, controls
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(group A), i.v. pirarubicin 2 mg kg-' (group B), and i.port.
pirarubicin 2 mg kg-' (group C). Both treatments were
administered in single doses 7 days after tumour inoculation.
Fourteen days later, the rabbits were sacrificed for his-
tological study. Hepatic tumour invasion was analysed by the
number of nodules present at 21 days and by their cross-
sectional area. Extrahepatic dissemination was evaluated by
the presence or absence of lung metastases in each group. A
lung metastasis ratio was defined as the ratio between the
number of rabbits with lung metastases and the total number
of rabbits in each group.
Statistical analysis
Biological and pharmacokinetic results were compared using
the Student's t-test. The number of liver nodules and tumour
areas were compared after transformation ofeach measure so
that Y = Vx for hepatic nodes, and Y = log x for cross-
sectional areas in order to approximate to normal probability
distributions and equalise variances.
Analysis of data for lung metastases was done with Pear-
son's exact chi squared test (Mehta & Patel, 1983), and
Fisher test 2 x 2. Significance was assumed for all tests at
P<0.05.
tological toxicity, and 3 mgkg-' was invariably lethal. After
i.port. administration, hepatic toxicity only occurred at doses
of 3.5 mg kg-' with the onset of mild centrolobular hepatic
necrosis and periportal fibrosis with limited and reversible
increases (2 x) of ALT and AST. Lower doses did neither
produce alterations of liver tests, nor induce histologic
modifications. However i.port. administration had to be
limited at 3 mg kg-' because of leucopenia. In order to com-
pare the same dose of i.v. and i.port. pirarubicin, and to
avoid the risk of mortality with high doses of pirarubicin, we
chose a 2 mg kg-' dose for all subsequent experiments.
Pharmacokinetics
Plasma concentrations of pirarubicin following either i.v. or
i.port. administration are depicted in Figure 3. In all cases,
plasma decay was biphasic and fitted to a two-compartment
model. Intraportal pirarubicin infusion led to a significant
2-fold decrease in both the peak plasma concentration of
pirarubicin (Cmax), and the AUC, when compared to the i.v.
route (Table I). Plasma metabolite levels (doxorubicin, dox-
orubicinol, pirarubicinol) remained constantly low, and no
significant difference was observed between the two routes of
administration (data not shown).
Results
Experimental model
Operative mortality in rabbits due to surgery or anaesthesia
was approximately 10%, and successful grafting was
obtained in 92.3% of cases. Tumour nodules were not yet
macroscopically detectable at 7 days, but microscopic
analysis of livers showed the presence of tumourous thrombi
starting to extend from the portal vein (Figure 2). No lung
metastases were observed. On day 14, two of five rabbits
presented macroscopic nodules with diameters exceeding
5 mm, and one had a lung metastasis. On day 21 all rabbits
had macroscopic tumours and three of four rabbits already
had lung metastases. These data justified (in accordance with
our study objectives) the choice of day 7 for studying the
effects of an early adjuvant treatment with pirarubicin.
Tolerance ofiport. pirarubicin
After i.v. administration, the maximal tolerated dose is
2 mg kg-'. Doses above 2 mg kg-' caused severe hema-
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Figure 3 Plasma concentrations of pirarubicin in rabbits follow-
ing an intravenous (i.v.) or intraportal (i.port.) administration of
a 2 mg kg dose. Concentrations were determined by HPLC. 0,
i.v.; *, i.port. Each point represents the mean of measurements
(± s.e.) done in eight rabbits.
Figure 2 Liver specimen of a rabbit sacrificed 7 days after intraportal injection of VX2 cancer cells. The arrow points to a
neoplastic intraportal thrombus.280 L.H. RAMIREZ etal.
Table I Comparison of pharmacokinetic parameters after i.v. and
i.port. pirarubicin administration
AUC Cmax
(ngmlmin) (ng ml)
flVd*
(I kg)
Half life (min)
Alpha Beta
i.v. 8080± 680 470± 60 20.42 1.8 77
i.port. 3831 ± 776 207± 43 48.04 1.1 69
P<0.01 P<0.01 P<0.01
*Apparent B volume of distribution.
Antitumour effects ofpirarubicin
In view of the pharmacokinetic advantages observed for the
i.port. administration of pirarubicin, the antitumour effects
were compared after i.v. or i.port. treatment against controls
(Figure 4). Both treatments reduced the hepatic tumour
growth, measured by the mean number of nodules and the
mean tumour cross-sectional areas. The mean number
(± s.d.) of nodules was 8.62 (± 5.4) for controls, 4.62 (± 3.2)
after i.v. treatment, and 2.25 (± 1.4) after i.port. treatment.
The ratio between the number of nodules of each treated
group and the number of nodules of the control group was
0.54 for the i.v. route and 0.26 for the i.port. route. Com-
parisons between groups showed statistically significant
differences between the control group and the i.port. group
(P<0.05), but not between the control and the i.v. groups,
or between the i.v. and the i.port. groups. The mean (± s.d.)
cross-sectional area (cm2) was 6.31 (± 6.1) for controls, 1.31
(± 2.2) after i.v. treatment, and 0.43 (± 0.4) after i.port.
treatment. The ratio between the area of each treated group
and the area of the control group was 0.21 for the i.v. route
and 0.07 for the i.port. route. Comparisons between groups
again showed statistically significant differences between the
control group and the i.port. group (P<0.05), but not
between the control and the i.v. groups, or between the i.v.
and the i.port. groups. Tumour growth was also evaluated at
extrahepatic sites of dissemination, as lungs. A significant
difference was observed between i.port. and i.v. treatments,
as fewer animals presented microscopic lung metastases after
i.port. treatment. Only one of eight rabbits (12.5%) treated
by the i.port. route had macroscopic or microscopic metas-
tases, whereas six of eight rabbits (75%) treated by the i.v.
route and seven of eight controls (87.5%) had lung involve-
ment (i.port. vs i.v., P<0.02). No differences were observed
between the i.v. group and the control group.
Mean number Mean cross- Lung
of tumours sectional area metastases
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Figure 4 Antitumour effects of pirarubicin. Control, black bars;
i.v. pirarubicin, dotted bars; i.port. pirarubicin hatched bars. a,
Mean number of tumours: control = 8.62 (± 5.4), i.v. = 4.62
(± 3.2), i.port. = 2.25 (± 1.4); controls vs i.port. = P <0.05. b,
Mean cross-sectional area (cm2): control = 6.31 (± 6.1),
i.v. = 1.31 (± 2.2), i.port. = 0.43 (± 0.4); control vs
i.port. = P <0.05. c, Lung metastases ratio (rabbits with lung
metastases/total number of rabbits in each group, x 10): cont-
rol = 8.75, i.v. = 7.5, i.port. = 1.25; control vs i.port. = P <0.02,
i.v. vs i.port. = P < 0.05.
Discussion
The rabbit VX2 tumour is a useful model for the study of
regional cancer therapy. Cell suspensions are relatively easy
to inoculate into the liver, and tumour growth kinetics can be
followed from the stage of endoluminal thrombi to that of
macroscopic multiple tumour nodules with secondary locali-
sations in the lungs. As nodules between 0.5 and 2 mm in
diameter are mainly vascularised by the portal vein branches
(Conway et al., 1983; Ackerman, 1986), theoretically they are
ideal targets for early i.port. perfusions. Later when tumour
neovascularisation is well developed in larger tumours, i.a.h.
chemotherapy will be more effective as previously shown in
experimental and human tumours (Butler et al., 1989; Daly
et al., 1987). Thus i.port. and i.a.h. routes of chemotherapy
are directed at two different clinical situations and cannot be
compared in terms of efficacy.
Intraportal administration of pirarubicin was mildly
hepatotoxic and dose-limiting myelosuppression was
observed at 3 mg kg-'. Therefore up to a 50% dose increase
can be delivered via the i.port. route. This correlates with our
pharmacokinetic data, which show a 2-fold decrease in the
AUC after i.port. administration compared to that obtained
via the i.v. route.
As i.port. pirarubicin proved to be both safe and well
tolerated, we decided to compare the antitumour effects of
the drug on early implants of VX2 cells after i.v. or i.port.
treatment. Although it is possible to deliver higher doses of
pirarubicin by the i.port. route than by the i.v. route, the
same dose was given to both treated groups. Because of this
choice, our study has focused on an evaluation of the
advantages of the regional vs the systemic route. Moreover it
enabled us to limit mortality in rabbits due to postoperative
infections induced by pirarubicin-related leucopenia.
In our study, we observed a constant benefit in favour of
i.port. chemotherapy when compared to both the control
group or the i.v. group. The hepatic tumour growth was
significantly reduced after a i.port. infusion, but in contrast,
i.v. infusion did not achieve any significant inhibition. Com-
paring the i.v. and the i.port. route, although the differences
on hepatic involvement were not significant, a trend indicated
a benefit for the rabbits treated by the i.port. route (see
Figure 4). These findings are comparable to the results of
some clinical trials which have shown a decrease in the
number of hepatic recurrences in i.port. treated groups
(Taylor et al., 1985; Wereldsma et al., 1990) compared to
control groups, but which did not include i.v. treated groups.
Only one clinical trial with an i.v. arm has so far shown
differences in overall survival after i.port. perfusions com-
pared to controls and i.v. treated patients (Gray et al., 1987).
An additional benefit of pirarubicin is conceivable if the
maximal i.port. tolerated dose, or a schedule of multiple
i.port. doses is administered. This could undoubtedly lead to
significant differences between i.port. and i.v. routes. Dose-
limiting side effects (myelosuppression) or repeated
laparotomy precluded this possibility during the course of
our experiments.
Notwithstanding, i.port. administration at single non-toxic
doses, was significantly more efficient than i.v. perfusion in
preventing extrahepatic dissemination. An explanation for
this enhanced antitumour effect on extrahepatic sites rather
than on the liver, could be that local drug concentrations
may produce sublethal effects which are unable to completely
eradicate tumour cells, but are capable of damaging a sub-
population of cells with a high metastatic potential and thus
interfere with a critical step in the metastatic cascade (Fidler
& Poste, 1985; Poupon, 1986; Weiss, 1992). We did not
explore whether the survival of this rabbit population
benefited from this reduction in secondary metastases after
i.port. chemotherapy. A clinical trial which failed to show
any difference in the rates of liver recurrences, did however
attain a better overall survival with i.port. perfusions (Wol-
mark et al., 1990), which may possibly be related to less
extrahepatic metastases. It has been suggested that i.port.
perfusions could work as a particular kind of 'systemicINTRAPORTAL EFFICACY OF PIRARUBICIN 281
therapy'. We believe that this is not the case, and that i.port.
perfusions may have their own biological specificity, because
of their effect on early metastatic cells before a subsequent
migration to other sites.
Intraportal injections of single non toxic doses of
pirarubicin offer an improved selective advantage over i.v.
injections but further experiments are warranted to determine
their optimal use. For the present, a clinical trial with i.a.h.
administration of pirarubicin has already yielded promising
results in hepatic metastasis of colorectal origin (Munck et
al., 1990). With a better dose-response relationship,
pirarubicin may indeed prove to be effective against colorec-
tal metastases otherwise refractory to anthracyclines. Thus a
rationale for adjuvant i.port. administration of pirarubicin
after resection of colorectal carcinoma may exist based on its
effects on hepatic synchronous metastases as well as secon-
dary extrahepatic metastatic dissemination.
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